Aristotle University Of Thessaloniki (AUTH)
Σχεδιασμός, σύνθεση και φαρμακοχημική μελέτη υβριδικών μορίων με πιθανή δράση έναντι της νόσου Alzheimer
Abstract
dc:descriptionAlzheimer's disease (AD) is the leading cause of dementia worldwide and the population of AD patients continues to grow, yet no new treatments have been approved in the last decade. AD is a multifactorial disease related to neuroinflammation, oxidative stress and AChE.The existing treatments may temporarily improve the symptoms, however the disease is not cured radically and, in many cases, intense side effects of the drugs occur.Multifactorial diseases, such as Alzheimer's disease, have many different drug targets, so treatments of these diseases can be achieved using drugs that target multiple molecular targets.The research approach of hybrid drugs offers significant advantages in the fight against multifactorial diseases.Knowing from previous studies that curcumin analogues as well as cinnamic acids show a strong anti-inflammatory effect, the main purpose of this thesis is the synthesis of new hybrid molecules from the combination of cinnamic acids with curcumin analogues, which inhibit lipid peroxidation, lipoxygenase, cyclooxygenase 2 and acetylcholinesterase to have a pleiotropic effect.In this thesis, with the help of previous quantitative structure-activity relationships (2D-QSAR) and binding studies, a library of hybrid molecules was designed with the aim of developing new inhibitors of LOX, COX-2 and AChE. The molecules were evaluated in silico in terms of their metabolic profile, their pharmaco-similarity and their pharmacokinetics.The new hybrid compounds synthesized were identified and evaluated in vitro for their potential antioxidant activity through inhibition of linoleic acid peroxidation (AAPH) as well as their potential anti-inflammatory activity through inhibition of COX-2 and LOX enzymes. Their ability to inhibit AChE was also evaluated. Can3c6 and Can2c2 derivatives showed sufficient multifactorial activity with APPH :82.2%, LOX IC50 :67.5μM, COX-2 IC50 :67.5μM and APPH :91%, LOX IC50 :52μM, AChE IC50 :70μM.In addition, the same compounds were tested for their ability to bind to interleukin 6 (IL-6), an inflammatory factor associated with neuroinflammation. Also evaluated with the same technique were the compounds Can5c9 and Can6c2, which showed the strongest activity in the inhibition of COX-2 (1 µM) and LOX (37.5 µM) respectively.The pleiotropic compound Can2c2 (inhibition rate of lipid peroxidation: 91%, IC50 (SLOX-1): 52 µM), COX-2: 19% and IC50 (AChE): 70 µM was selected to study its in vitro ability to inhibit the aggregation of pathological ATXN1 (ATXN1Q82), in the neural cell line SH-SY5Y.Finally, the effect of the new pleitropic compounds Can3c6 and Can2c2 on the functional recovery observed after rat sciatic nerve crush was studied in vivo in Wistar rats. Nerve regeneration of the sciatic nerve was established by behavioral experiments such as sensory recovery test and motor assessment.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chainoglou, Eirini
- Χαΐνογλου, Ειρήνη
Subjects
dc:subject × 20- Ανάλογα κουρκουμίνης
- Κινναμωμικά οξέα
- Υβρίδια
- Αλτσχάϊμερ, νόσος
- Αναστολή Λιποξυγονάσης (LOX)
- Ανατολή Κυκλοξυγενάσης - 2 (COX-2)
- Αναστολή Ακετυλοχολινεστεράσης (AChE)
- Curcumin analogues
- Cinnamic acids
- Hybrids
- Alzheimer’s disease
- Lipoxygenase inhibitors
- Cyclooxygenase-2 Inhibitors
- Acetylcholinesterase Inhibitors
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακευτική χημεία
- Basic Medicine
- Medical and Health Sciences
- Medicinal chemistry
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53245